Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: A systematic review and meta-analysis

Rheumatology (United Kingdom)

Volumn 55, Issue 3, 2016, Pages 573-582

  Goodman, Susan M ^a   Menon, Indu ^b   Christos, Paul J ^a   Smethurst, Rie ^c   Bykerk, Vivian P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Hospital for Special Surgery   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Arthroplasty.; Perioperative management; Rheumatoid arthritis; Surgical site infection; Tumour necrosis factor inhibitors

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PREDNISONE; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTHROPLASTY; ARTICLE; BACTERIAL ARTHRITIS; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COCHRANE LIBRARY; CORTICOSTEROID THERAPY; DATA EXTRACTION; DRUG EXPOSURE; ELECTIVE SURGERY; EMBASE; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; JOINT PROSTHESIS; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; ODDS RATIO; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REPLACEMENT ARTHROPLASTY; RHEUMATOID ARTHRITIS; SURGICAL INFECTION; SURGICAL RISK; SYSTEMATIC REVIEW;

EID: 84965010988     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev364     Document Type: Article

References (40)

1. Bombardier C, Barbieri M, Parthan A et al. The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. Ann Rheum Dis 2012;71:836-44.
2. Strand V, Sharp V, Koenig AS et al. Comparison of healthrelated quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012;71:1143-50.
3. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
4. Kremer JM, Weinblatt ME, Bankhurst AD et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003;48:1493-9.
5. Mertelsmann-Voss C, Lyman S, Pan TJ et al. US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis. Arthritis Rheumatol 2014;66:1432-9.
6. Goodman SM, Johnson B, Huang WT et al. Rheumatoid arthritis (RA) patients have simlar excellent outcomes after total knee replacement compared with osteoarthritis (OA) patients. Ann Rheum Dis 2013;72:A586.
7. Goodman SM, Ramsden-Stein DN, Huang WT et al. Patients with rheumatoid arthritis are more likely to have pain and poor function after total hip replacements than patients with osteoarthritis. J Rheumatol 2014;41:1774-80.
8. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004;25:331-5.
9. Berthold E, Geborek P, Gulfe A. Continuation of TNF blockade in patients with inflammatory rheumatic diseas. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures. Acta Orthop 2013;84:495-501.
10. Berbari EF, Hanssen AD, Duffy MC et al. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 1998;27:1247-54.
11. Au K, Reed G, Curtis JR et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:785-91.
12. Grijalva CG, Chen L, Delzell E et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306:2331-9.
13. Bongartz T, Halligan CS, Osmon DR et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1713-20.
14. Galloway JB, Hyrich KL, Mercer LK et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:1810-4.
15. Zimmerli W, Moser C. Pathogenesis and treatment concepts of orthopaedic biofilm infections. FEMS Immunol Med Microbiol 2012;65:158-68.
16. Nogi S, Hashimoto A, Iwata K et al. [Case of immunosuppressant- resistant amyopathic dermatomyositis with rapidly progressive interstitial pneumonia ameliorated after resection of gastric cancer]. Nihon Rinsho Meneki Gakkai Kaishi (Jpn J Clin Immunol) 2012;35:188-93.
17. Ding T, Ledingham J, Luqmani R et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 2010;49:2217-9.
18. Pham T, Claudepierre P, Deprez X et al. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Societe Francaise de Rhumatologie, SFR). Joint Bone Spine 2005;72:S1-58.
19. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
20. Bombardier C, Hazlewood GS, Akhavan P et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol 2012;39:1583-602.
21. Bartelds GM, Krieckaert CL, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
22. Curtis JR, Patkar N, Xie A et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33.
23. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
24. Ng B, Aslam F, Petersen NJ, Yu HJ, Suarez-Almazor ME. Identification of rheumatoid arthritis patients using an administrative database: a Veterans Affairs study. Arthritis Care Res 2012;64:1490-6.
25. Momohara S, Kawakami K, Iwamoto T et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 2011;21:469-75.
26. Kubota A, Sekiguchi M, Nakamura T, Miyazaki Y, Suguro T. Does use of a biologic agent increase the incidence of postoperative infection in surgery for rheumatoid arthritis after total joint arthroplasty? Mod Rheumatol 2014;24:430-3
27. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999;27:97-132.
28. OCEBM LoEWG. The Oxford 2011 Levels of Evidence, 2011. www.cebm.net (10 May 2014, date last accessed).
29. Hudak PL, Cole DC, Haines AT. Understanding prognosis to improve rehabilitation: the example of lateral elbow pain. Arch Phys Med Rehabil 1996;77:586-93.
30. Kubota A, Nakamura T, Miyazaki Y, Sekiguchi M, Suguro T. Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol 2012;22:844-8.
31. Scherrer CB, Mannion AF, Kyburz D, Vogt M, Kramers-de Quervain IA. Infection risk after orthopedic surgery in patients with inflammatory rheumatic diseases treated with immunosuppressive drugs. Arthritis Care Res 2013;65:2032-40.
32. Johnson BK, Goodman SM, Alexiades MM et al. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol 2013;40:617-23.
33. Kawakami K, Ikari K, Kawamura K et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers:perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology 2010;49:341-7.
34. Hirano Y, Kojima T, Kanayama Y et al. Influences of antitumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol 2010;29:495-500.
35. den Broeder AA, Creemers MC, Fransen J et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007;34:689-95.
36. Ruyssen-Witrand A, Gossec L, Salliot C et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 2007;25:430-6.
37. Giles JT, Allison M, Bingham CO III, Scott WM Jr, Bathon JM. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum 2009;61:1248-56.
38. Giles JT, Bartlett SJ, Gelber AC et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55:333-7.
39. New York State Department of Health. Hospital-Acquired Infections 2012. http://www.health.ny.gov/statistics/- facilities/hospital/hospital-acquired-infections/2012/ docs/hospital-acquired-infection.pdf (10 May 2014, date last accessed).
40. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999;150:327-33.